Dr. Wang obtained his medical degree from Shanghai Medical University in 1982. Following a practice as an orthopedic surgeon in Shanghai, he attended UCLA School of Medicine and the Institute of Animal Physiology at Cambridge, U.K. to further his professional training. He was awarded a Ph.D. degree in physiology by University of Cambridge in 1989 and started his research career a year later in several US-based biotechnology companies, including Amylin Pharmaceuticals and Ligand Pharmaceuticals. In the mid-90’s, he served as a consultant to Merck and UNDP relative to China-related healthcare projects. Thereafter, he was heavily involved in entrepreneur activities and co-funded several biopharmaceutical start-up companies in the U.S., U.K., China and Hong Kong.

Over the past 32 years, Dr. Wang has published more than 150 research papers in English, received a number of academic awards or social honors from the U.K., U.S., Taiwan and China, and obtained 62 international patents. He has been an adjunct professor at Nanjing University since 1993. Currently, he holds membership status in the American Medical Association, Chinese Medical Association, Formosan Medical Association and Asia-Pacific International Network of Molecular Biology. He was elected as a fellow of the Royal Society of Medicine (U.K.) in 1987 and a fellow of the Institute of Biology (U.K., now as Society of Biology) in 2001. Dr. Wang was appointed as a professor of pharmacology at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS) and executive deputy director of the National Center for Drug Screening in 2001. In 2003, he was promoted to the full directorship and served as assistant president, Shanghai Institutes for Biological Sciences, CAS (between 2003 and 2004). In 2004, Dr. Wang was appointed by the Shanghai Pudong New District Government as a senior advisor on the biopharmaceutical industry and elected as the first president of Shanghai Pudong Engineers Association (re-elected in 2009 and 2013, respectively). He is also a member of the Board of Trustees of the Novo Nordisk-CAS Research Foundation (since 2007). In 2008, the Scripps Research Institute (USA) appointed Dr. Wang as an Adjunct Professor, and in May 2010, Li Ka Shing Faculty of Medicine, University of Hong Kong made him Honorary Professor of Pharmacology. Meanwhile, the WHO/TDR named him as one of the 12 expert members for the Thematic Reference Group on Innovation and Technology, Shanghai Clinical Research Center appointed him as a Senior Advisor on International Business Affairs and Chinese Academy of Medical Sciences/Peking Union Medical College made him Guest Professor. In 2011, he formally took the 1st directorship of the newly established Chinese National Compound Library and has become Chair Professor at South China University of Technology in Guangzhou and Editorial Board Member of Trends in Pharmacological Sciences (TiPS). He was appointed as an Editor of Biochemical Journal in 2012 and adjunct professor at University of Macau in 2014. Dr. Wang’s research achievements include the discovery of the non-peptidic glucagon-like peptide-1 receptor agonist (Boc5) and the determination of the 3-D structure of the human glucagon receptor. In addition, his achievements includes the first discovery of the non-peptide small molecule modulators (including agonists and antagonists) targeting formyl peptide receptor 1; the clarification of molecular targets for effective components of the traditional Chinese medicine isochamaejasmin; the identification of new pharmacological mechanism of commonly used immunosuppressant cyclosporin A; the discovery of raloxifene derivatives for the treatment of breast and prostate cancer and a new type of androgen receptor modulators.

EDUCATION
02/1978–12/1982, M.B. , Shanghai First Medical College, Shanghai, P.R. China
10/1986–09/1989, Ph.D. (Cantab) in Physiology, University of Cambridge, U.K.

WORK EXPERIENCE
1. 01/1983 06/1984, Resident training as a microsurgeon at Department of Orthopedics, Shanghai Sixth People's Hospital, Shanghai 200040, P.R. China.
2. 07/1984 06/1985, Postdoctoral Research Associate at the Rehabilitation Center, School of Medicine, University of California at Los Angeles (UCLA), CA 90024, U.S.A.
3. 10/1985 09/1986, Research Scientist at Department of Physiology and Department of Immunology, AFRC Institute of Animal Physiology, Babraham, Cambridge CB2 4AT, England, U.K.
4, 10/1986 11/1989, Research Student for Ph.D. at St. Edmund’s College, University of Cambridge, Cambridge CB3 0BN, England, U.K. and AFRC Institute of Animal Physiology and Genetics Research, Babraham, Cambridge CB2 4AT, England, U.K.
5. 12/1989 05/1990, Senior Research Associate at Department of Surgery, University of Cambridge Clinical School, Level 9, Addenbrooke's Hospital, Hills Road, Cambridge CB2 2QQ, England, U.K.
6. 06/1990-07/1992, Scientific Investigator at Department of Physiology, Amylin Pharmaceuticals, Inc. (formerly as Amylin Corporation), 9373 Towne Centre Drive, Suite 250, San Diego, CA 92121, U.S.A.
7. 08/1992-07/1996, Senior Research Manager at Department of Pharmacology, Ligand Pharmaceuticals, Inc., 9393 Towne Centre Drive, San Diego, CA 92121, U.S.A.
8. 04/1993-present, Concurrent Professor at Department of Biochemistry, Nanjing University, 22 Han Kou Road, Nanjing 210008, P.R.C.
9. 08/1996-12/1997, Board Member of GC BioTechnologies, LLC, 850 Lincoln Centre Dr., Foster City, CA 94404, U.S.A.
10. 01/1998-06/2000, Chairman and General Manager, Shanghai GeneCore BioTechnologies Co., Ltd., 3rd Floor, 200 Tian Lin Road, Shanghai 200233, P.R.C.
11. 07/2000-11/2001, Vice-Chairman of the Board, Ancile Pharmaceuticals, Inc., 10555 Science Center Drive, San Diego, CA 92121, U.S.A.
12. 12/2001-present, Professor of Pharmacology (Level 2), Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road , Shanghai, P.R.C.
13. 12/2001-07/2003, Executive Deputy Director, the National Center for Drug Screening, 189 Guoshoujing Road, Shanghai 201203, P.R.C.
14. 08/2003-present, Director, the National Center for Drug Screening, 189 Guoshoujing Road, Shanghai 201203, P.R.C.
15. 07/2008-present, Adjunct Professor, Molecular and Integrative Neurosciences Department (MIND), The Scripps Research Institute, 10550 North Torrey Pines Road, SR-307, La Jolla, CA 92037, U.S.A .
16. 07/2008-06/2010, Affiliate Professor, Center for Chemical Genomics, Burnham Institute for Medical Research, 10901 North Torrey Pines Road, La Jolla, CA 92037, U.S.A.
17. 04/2010-present: Honorary Professor of Pharmacology, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, University of Hong Kong, 21, Sassoon Road, Hong Kong, P.R.C.
18. 04/2010-12/2011, Member, the Thematic Reference Group on Innovation and Biotechnology, UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training for Tropical Diseases (TDR), Geneva, Switzerland.
19. 05/2010-present, Senior Advisor on International Business Affairs, Shanghai Clinical Research Center, Shanghai, P.R.C.
20. 07/2010-06/2013, Guest Professor, Chinese Academy of Medical Sciences/Peking Union Medical College, Beijing, P.R.C.
21. 10/2011-present, Chair Professor, School of Biotechnology and Engineering, South China University of Technology, Guangzhou, P.R.C.
22. 01/2012-present, Director, Chinese National Compound Library, Building 5, 3728 Jinke Road, Shanghai, P.R.C.
23. 06/2014-present, Adjunct Professor, University of Macau, Av. Padre Tomás Pereira Taipa, Macau, P.R.C.

1. Structures and functions of G-protein coupled receptors (GPCRs)
1) structures and functions of class B GPCRs associated with metabolic diseases;
2) potential roles of RXFP4 (GPCR142) in type 2 diabetes;
3) impact of GPR160 (oGPCR) on prostate cancer cell cycle and apoptosis;
4) formyl peptide receptor 1 (FPR1) gene polymorphism and cyclosporine responses.

2. High-throughput screening and structure optimization of active compounds
1) discovery of small molecule anti-depressants based on 3-D structure of CRF1R;
2) high-throughput screening and pharmacological evaluation for small molecule transcription regulators of thioredoxin interacting protein (TXNIP); 3) high-throughput screening for inhibitors of PI3K subtype P110 α mutant PIK3CA-H1047R;
4) high-throughput screening for inhibitors of histone methyltransferase (EZH2) Y641F mutant;
5) structure-activity relationship study on euchromatic histone methyltransferase 1/2 (EHMT1/2) inhibitors;
6) targets-based high-throughput screening for agents against tuberculosis, schistosomiasis and filarial pathogens.

3. Novel technologies and methods for drug screening Application of a real-time, label-free technology in functional studies of pancreatic islet β cells and activation of T cells.

1. Major National Science and Technology Projects (12th five-year plan) Merit-based Grant ,Resource building and applications of the Chinese National Compound Library ,Project Leader ,2015.1-2018.12
2. International Cooperation, Ministry of Science and Technology, China, Developing new anti-cancer drugs against genetically defined targets ,Project Leader 2014.4-2017.3
3. The International Cooperation, Ministry of Science and Technology, China, International collaboration on drug and diagnostics innovation for tropical diseases in P.R. China, One of the Project Leaders, 2014.4-2017.4
4.  Science and Technology Commission of Shanghai Municipality, Shanghai technology and professional service platform for drug screening,Project Leader, 2013.7-2015.6
5. Major National Science and Technology Projects (12th five-year plan), Construction, development and resource sharing of the Chinese National Compound Library, Project Leader, 2012.1-2015.12
6.  Shanghai Science and Technology of Shanghai Municipality, Construction of an automatic storage and quality control system for large-scale compound library, Project Leader, 2012.1-2015.12
7. International Cooperation, Ministry of Science and Technology, China, International cooperation research on Chinese tropical disease medicine and diagnosis reagents, One of the Project Leaders, 2011.1-2013.12
8.  Major National Science and Technology Projects (11th five-year plan), Construction and application of a modern drug screening system and a large-scale compound library, Project Leader, 2009.1-2010.12
9.  The World Health Organization, Innovation on drugs against neglected diseases – a WHO research project, Project Leader, 2009.7-2011.7